Please assess the completion status of the following clinical trial:

Trial Title: Effect of Topical CBD Cream for Degenerative Hallux Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a new diagnosis of hallux rigidus or hallux valgus~* VAS pain score of 4 or higher~* Age \> 18 years~* The patient provides informed consent~Exclusion Criteria:~* A previous operative procedure to the first metatarsal for treatment of hallux valgus or hallux rigidus~* VAS pain score at presentation less than 4~* Concomitant hallux valgus and hallux rigidus on the ipsilateral side~* Allergy to CBD, Cannabidiolic acid (CBDa) or any other ingredient contained in the topical cream~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mg-CBDa cream (Type: ACTIVE_COMPARATOR): Subjects in this group will receive the active Mg-CBDa (magnesium-cannabidiolic acid) for topical treatment of hallux valgus or hallux rigidus.
- Placebo cream (Type: PLACEBO_COMPARATOR): Subjects in this group will receive the inactive CBD cream for topical treatment of hallux valgus or hallux rigidus. The ingredients of the placebo cream are: butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), and food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.

Based on this trial design, predict the completion outcome and termination type (if applicable).